Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | STK4 | Q13043 | 4/20 | 0.32 |
| ▸ | STK3 | Q13188 | 4/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764383 | 0.90 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5766919 | 0.90 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5766570 | 0.90 | MAPK14 (0.50) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5764069 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11MAPK13MAPK12RAF1 | |
| SCHEMBL5763168 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL6223108 | 0.88 | MAPK14 (0.49) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5762828 | 0.87 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5765482 | 0.87 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL6218187 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL5765792 | 0.86 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK14 3902/4885MAPK11 3630/4885MAPK13 3723/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | MAPK14 4157/4885MAPK11 3723/4885MAPK13 3928/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | MAPK14 3593/4885MAPK11 3364/4885MAPK13 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.